Jonathan Rubin - Feb 23, 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Chief Medical Officer
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Feb 23, 2024
Transactions value $
-$16,477
Form type
4
Date filed
2/27/2024, 05:00 PM
Previous filing
Feb 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Award $0 +1.25K +31.58% $0.00 5.21K Feb 23, 2024 Direct
transaction SUPN Common Stock Tax liability -$16.5K -567 -10.89% $29.06 4.64K Feb 23, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -1.25K -25% $0.00 3.75K Feb 23, 2024 Common Stock 1.25K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F2 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F3 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.